Matrix metalloproteinase inhibitors prevent sepsis-induced refractoriness to vasoconstrictors in the cecal ligation and puncture model in rats  by de Souza, Priscila et al.
European Journal of Pharmacology 765 (2015) 164–170Contents lists available at ScienceDirectEuropean Journal of Pharmacologyhttp://d
0014-29
n Corr
Santa C
88.040-
E-mjournal homepage: www.elsevier.com/locate/ejpharCardiovascular pharmacologyMatrix metalloproteinase inhibitors prevent sepsis-induced
refractoriness to vasoconstrictors in the cecal ligation and puncture
model in rats
Priscila de Souza a, Richard Schulz b, José Eduardo da Silva-Santos c,n
a Department of Pharmacology, Universidade Federal do Paraná, Curitiba, PR, Brazil
b Departments of Pediatrics & Pharmacology, Cardiovascular Research Centre, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB,
Canada
c Laboratory of Cardiovascular Pharmacology, Department of Pharmacology, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazila r t i c l e i n f o
Article history:
Received 24 April 2015
Received in revised form
17 August 2015
Accepted 18 August 2015
Available online 20 August 2015
Keywords:
Vasoplegia
Matrix metalloproteinase-2
Calponin-1
Septic shockx.doi.org/10.1016/j.ejphar.2015.08.030
99/& 2015 Elsevier B.V. All rights reserved.
espondence to: Department of Pharmacolo
atarina, Campus Universitário, Trindade, Blo
900, Brazil.
ail address: j.e.silva.santos@ufsc.br (J.E. da Silva b s t r a c t
Previous studies have shown that the loss of contractility in aortas from lipopolysaccharide (LPS)-treated
rats is related to intracellular activation of matrix metalloproteinase (MMPs). However, the role of MMPs
in the vascular refractoriness to vasoconstrictors has not been investigated in a model of polymicrobial
sepsis. We evaluated the effects of the oral administration of the MMP inhibitors doxycycline or ONO-
4817 in the in vitro vascular reactivity of aortic rings from rats subjected to the cecal ligation and
puncture (CLP) model of sepsis. Both doxycycline and ONO-4817 did not change vascular responses in
sham-operated rats, but fully prevented hyporeactivity to KCl, phenylephrine and angiotensin II in
vessels from CLP rats. This protective effect was not associated with changes in hematological parameters
or blood nitrate and nitrite. The refractoriness to contractile agents was accompanied by enhanced ac-
tivity of MMP-2 in aorta from CLP rats, which was abrogated by MMP inhibitors. CLP-induced sepsis did
not impair the levels of MMP-2 in aorta, but signiﬁcantly reduced calponin-1, a regulatory protein of
vascular contraction. In addition, augmented levels of TIMP-1 were found in vessels from CLP rats. All
these differences were prevented by either doxycycline or ONO-4817. Our study shows, for the ﬁrst time
in the CLP rat model of sepsis, that the vascular refractoriness to different contractile agents induced by
polymicrobial sepsis is associated with increased activity of MMP-2 and reduced amounts of calponin-1
in the aorta. These ﬁndings reinforce the importance of the enhanced activity of MMPs for vascular
failure in septic shock.
& 2015 Elsevier B.V. All rights reserved.1. Introduction
Matrix metalloproteinases (MMPs) were described in verte-
brates in early 1960s (Gross and Lapiere, 1962) and had their role
in the remodeling of extracellular matrix extensively investigated.
The wide distribution of MMPs in different cell types, including
human monocytes, neutrophils, smooth muscle cells and en-
dothelial cells, stimulated investigations to characterize the in-
volvement of the proteolytic activity of MMPs in several biological
processes. The participation of MMPs in human inﬂammatory
conditions, such as arthritis (Okada et al., 1989), periodontal dis-
ease (Golub et al., 1997), and atherosclerosis (Galis et al., 1994), is
now well characterized (for review see Castro et al., 2011; Hu et al.,gy, Universidade Federal de
ck D/CCB, Florianópolis, SC
a-Santos).2007; Parks et al., 2004). The attention for the involvement of
MMPs in sepsis was raised by the demonstration of high levels of
MMP-9 in the blood of non-surviving septic patients, which was
associated with increased amounts of monocyte MMP-9 mRNA
and was reduced after removal of bacterial lipopolysaccharide
(LPS) from blood (Nakamura et al., 1998). Subsequent studies re-
inforced the ability of LPS and several other inﬂammatory med-
iators to induce an in vitro rapid release of MMP-9 in whole human
blood (Pugin et al., 1999), comparable to the release of MMP-9 in
the blood of healthy humans after LPS injection (Albert et al.,
2003; Pugin et al., 1999). Inhibition of MMPs in vivo prevented the
lung injury (Carney et al., 2001) and protected against the lethality
associated with endotoxemia (Hu et al., 2005) and with the cecal
ligation and puncture (CLP) model of sepsis in rats (Steinberg et al.,
2003).
Severe sepsis and septic shock involve an exacerbated in-
ﬂammatory process and are accompanied by a progressive re-
duction in blood pressure, which is refractory to ﬂuid infusion and
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organs, contributing to multiple organ failure and the high rate of
sepsis-associated mortality (for review see Dellinger, 2003). In-
terestingly, the inhibition of MMPs in both in vitro (Lalu et al.,
2006) and in vivo (Cena et al., 2010) approaches prevented LPS-
induced hyporeactivity to vasoconstrictors, and the MMP-2 activ-
ity was augmented in homogenates of aorta taken from en-
dotoxemic rats, in a manner fully dependent on the presence of
endothelial cells and nitric oxide production (Cena et al., 2008).
Nevertheless, if on one hand high blood levels of active MMPs
have been clearly associated with reduced survival in both ex-
perimental and clinical studies, on the other hand the evidence of
their involvement in vascular dysfunction are restrict to the de-
monstration of a role for MMP-2 in the hyporeactivity to vaso-
constrictors in vessels from LPS-injected rats (Castro et al., 2012;
Cena et al., 2010). Importantly, although well accepted as an ex-
perimental model of sepsis, endotoxemia does not reproduce
several clinical aspects of sepsis (Buras et al., 2005; Dejager et al.,
2011; Rittirsch et al., 2009).
In this light, this study was designed to investigate if MMPs also
play a role in the development of vasoplegia during the poly-
microbial sepsis induced by CLP, an experimental model that clo-
sely resembles the clinical progression and characteristics of hu-
man septic shock.2. Material and methods
2.1. Drugs and reagents
N-[(1S,3S)-1-[(Ethoxymethoxy)methyl]-4-(hydroxyamino)-3-
methyl-4-oxobutyl]-4-phenoxybenzamide (ONO-4817; a kind gift
from ONO Pharmaceutical, Osaka, Japan); doxycycline, acetylcho-
line, phenylephrine, angiotensin II, gelatin type A from porcine
skin, Coomassie brilliant blue (G-250), Tris–HCl, sucrose, leu-
peptin, soybean trypsin inhibitor, aprotinin, protease inhibitor
cocktail (Sigma-Aldrich, Oakville, ON, CA); dithiothreitol (Fisher
Scientiﬁc, Ottawa, ON, CA); antibodies against β-actin, calponin-1,
smoothelin-B (Santa Cruz, Dallas, TX, USA), MMP-2 (Millipore,
Mississauga, ON, CA), TIMP-1 (Calbiochem, EMD Millipore, Mis-
sissauga, ON, CA) and TIMP-4 (Chemicon, Temecula, CA, USA);
Triton X-100 (Pierce, Thermo Scientiﬁc, Rockford, IL, USA); NaCl,
CaCl2, NaN3, KCl, CaCl2 2H2O, MgSO4, KH2PO4, NaHCO3, d-glucose
11.1 (Merck & Co, EMD Millipore, Mississauga, ON, CA).
2.2. Animals, experimental groups and treatment with matrix me-
talloproteinase inhibitors
Male Wistar rats (250–300 g) supplied by the University of
Alberta were used in the experiments. All procedures were ap-
proved by the Institutional Animal Care and Use Committee of
University of Alberta and were in compliance with the Canadian
Council on Animal Care Guide to the Care and Use of Experimental
Animals.
Two hours prior to surgery, animals used in both CLP and
sham-operated groups (n¼4–8 per group) received a single ga-
vage containing the MMP inhibitors ONO-4817 (100 mg/kg; Hariya
et al., 2004), doxycycline (15 mg/kg; Yaras et al., 2008), or 0.5%
carboxymethylcellulose (0.1 ml/100 g), the vehicle used to dilute
either of the MMP inhibitors. For comparison purposes, all ex-
periments were also performed in a group of naïve rats (n¼4).
2.3. Induction of sepsis by CLP
The CLP model was conducted as previously described (Rit-
tirsch et al., 2009) with minor modiﬁcations. Brieﬂy, the rats wereanesthetized with ketamine/xylazine (100/20 mg/kg, i.p.) and a
skin midline incision was performed after disinfection of the ab-
dominal area. The cecum was ligated distal to the ileocecal valve
(comprising 75%) and the antimesenteric cecal surface was punc-
tured with a needle (14 gauge, one hole), followed by a mild
compression for leakage of the intestinal content. The wound was
closed by interrupted sutures. After the surgery, all animals re-
ceived a postoperative ﬂuid resuscitation (sterile saline, 3 ml/
100 g, s.c.) to prevent dehydration, and buprenorphine (0.01 mg/
kg) to relieve pain. The animals were maintained in warmed cages
(35 °C) until the complete recovery of anesthesia. Sham-oper-
ated animals were subjected for the same procedures, with the
exception of the ligature or intestinal perforation.
2.4. Experimental setup for in vitro assessment of vascular
responsiveness
Six hours after the surgical procedure, the rats from CLP, sham-
operated or naïve groups were euthanized using an overdose of
sodium pentobarbital (100 mg/kg, i.p.). The thorax was opened
and the descending thoracic aorta was removed and cleaned of
connective tissue. The distal portion was immediately frozen in
liquid nitrogen and stored at 70 °C for biochemical analysis. The
proximal portion was cut into 3–4 mm ring-like segments and
mounted in tissue bath chambers containing Krebs solution
(composition, in mM: NaCl 115.3, KCl 4.9, CaCl2 2H2O 1.46, MgSO4
1.2, KH2PO4 1.2, NaHCO3 25, d-glucose 11.1; pH 7.4), maintained at
37 °C and continuously bubbled with 95% O2/5% CO2 gas mixture.
The tension was recorded via isometric force transducers (Grass
FT03) connected to a MP System (model MP150) coupled to Acq-
Knowledge 3.1 recording software (both from Biopac Systems,
Goleta, CA, USA).
The aortic rings were allowed to stabilize under a resting ten-
sion of 1.0 g for 60 min before the addition of any drug. During all
stabilization periods followed in our protocols the Krebs solution
was replaced every 15 min. After stabilization, the aortic rings
were exposed to 60 mM KCl and the contraction obtained was
recorded. The preparations were washed with Krebs solution and
after a new stabilization period of 30 min, phenylephrine, followed
by acetylcholine (both 1 mM), were added into the baths. The
ability of acetylcholine to induce at least 80% relaxation in phe-
nylephrine-contracted preparations was used to conﬁrm the in-
tegrity of their endothelium. Only endothelium-intact aortic rings
were used in this study.
After washing and following a new resting period of 60 min,
cumulative concentration response curves to phenylephrine (1 nM
to 3 mM) or angiotensin II (1 nM to 0.3 mM) were constructed. Each
preparation was exposed to only one of these vasoconstrictors. The
contractile effects of these vasoconstrictors were compared among
the groups.
2.5. Collection of blood, measurement of serum levels of nitrate and
nitrite and hematological analysis
Samples of blood were taken from the vena cava immediately
before the isolation of the thoracic aorta. Hematological para-
meters were evaluated in 10 μl of fresh blood collected from
control and CLP groups, with or without previous treatment with
doxycycline, using an automatized blood counter (HORIBA ABXs,
Micros 60; Montpellier, France). The remaining blood was cen-
trifuged at 7500 g for separation of serum, which was collected
and frozen at 70 °C. The serum was processed for the colori-
metric detection of nitrate and nitrite (NOx
−) using a commercial kit
(Cayman Chemical Company, Ann Arbor, MI, USA), following the
manufacturer's instructions.
Table 1
The reduction in the maximal contractile effect (Emax) in aortic rings at 6 h after CLP surgery is prevented by MMP inhibitors.
Naïve Sham-operated CLP
– Vehicle ONO-4817 Doxycycline Vehicle ONO-4817 Doxycycline
KCl [60 mM] 2.5270.24 2.1470.28 2.2370.28 2.2770.26 1.3670.11a 2.0970.16b 2.0470.09b
Phenylephrine [1 μM] 2.2970.29 2.1570.27 1.9770.24 2.0170.24 1.5470.19a 2.0670.26b 2.0270.25b
Angiotensin II [0.3 μM] 1.0970.17 0.8870.14 0.8170.10 0.8270.12 0.2870.04a 0.7970.13b 0.6870.12b
The values show the mean7standard error of the maximal contractile effects (Emax, in grams) obtained in vessels from 4–8 different animals per group. Sham-operated and
CLP rats were previously treated with ONO-4817 (100 mg/kg, p.o.), doxycycline (15 mg/kg, p.o.), or vehicle (0.5% carboxymethylcellulose, 0.1 ml/100 g), two hours before the
CLP or sham surgery.
a Po0.05 versus control (sham-operated) group.
b Po0.05 when compared with the CLP-vehicle group.
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For this assay the frozen aortas (70 °C) were crushed in liquid
nitrogen and homogenized on ice using a pellet pestle hand
homogenizer in a buffer containing Tris–HCl (50 mmol/L), sucrose
(3.1 mmol/L), dithiothreitol (1 mmol/L), leupeptin (10 mg/ml),
soybean trypsin inhibitor (10 mg/ml), aprotinin (2 mg/ml), protease
inhibitor cocktail (1:1000 v/v), and Triton X-100 (0.1%). After
homogenization, the samples were centrifuged at 10,000 g
(20 min, 4 °C), and the supernatants were collected for analysis.
The total protein concentration in the samples was determined by
the bicinchoninic acid assay, using a commercial kit (Sigma-Al-
drich, Oakville, ON, CA) and bovine serum albumin as standard.
Western blot analyses on the aortic extracts were performed as
previously detailed (Guarido et al., 2014). In brief, samples con-
taining 40 μg of protein were subjected for electrophoretic se-
paration in 10% polyacrylamide gel (SDS-PAGE), transferred onto a
polyvinylidene diﬂuoride membrane (BioRad, Hercules, CA, USA)
in Towbin buffer (20% v/v methanol, 25 mM Tris-base, 192 mM
glycine, 0.05% w/v sodium dodecyl sulfate), which were exposed
overnight to primary antibodies against β-actin (1:25000), calpo-
nin-1 (1:500), smoothelin-B (1:500), MMP-2 (1:1000), or TIMP-1
(1:500), followed by incubation with secondary antibodies
(1:5000) conjugated to horseradish peroxidase at room tempera-
ture for one hour. Enhanced chemiluminescence was used for
detection of protein levels by autoradiography, and the bands were
quantiﬁed by densitometry using the software ImageJ (NIH, USA).
Aliquots containing 20 μg of protein taken from the same aorta
homogenate prepared for Western blot were used to measure the
gelatinolytic activity of MMPs by zymography using 8% poly-
acrylamide gels copolymerized with gelatin (2 mg/ml), a substrate
of MMP-2. The supernatant of phorbol ester activated HT-1080
cells (American Type Culture Collection) was loaded and used as
an internal standard in all experiments. Following 90 min of
electrophoresis (at 90 V), the gels were washed with 2.5% Triton
X-100 for one hour at room temperature (with 20 min solution
changing intervals) to remove sodium dodecyl sulfate. The gels
were then maintained at 37 °C during 20 h in the incubation buffer
(50 mM Tris–HCl, 150 mM NaCl, 5 mM CaCl2, and 0.05% NaN3)
followed by staining with 0.05% Coomassie brilliant blue (G-250)
in a mixture of methanol, acetic acid and water (in the ration
2.5:1:6.5, v/v, respectively) for 2 h and destained in aqueous so-
lution of 4% methanol and 8% acetic acid (v/v) until the transparent
bands were detected against the dark blue background. The bands
were quantiﬁed by densitometry using the software ImageJ (NIH,
USA) and expressed as a ratio of the internal standard.
2.7. Statistical analysis
Results are expressed as mean7standard error of mean (S.E.
M.). Statistical signiﬁcance was determined using two-wayanalysis of variance (ANOVA), followed by Dunnett's multiple
comparisons test. A P value less than 0.05 was considered statis-
tically signiﬁcant. The graphs were drawn and the statistical ana-
lyses were performed using GraphPad Prism version 6 (GraphPad
Software, La Jolla, CA, USA).3. Results
3.1. MMP inhibitors prevent CLP-induced vascular refractoriness
without change NOx
− levels and blood cell count in septic rats
When compared with naïve and sham-operated animals, the
aortic rings from rats subjected to CLP showed marked hypor-
eactivity to vasoconstrictors (Po0.05, compared with the sham-
operated group), as shown by a reduction in the maximal contractile
effect (Emax) induced by phenylephrine, angiotensin II, and KCl
(Table 1). The pretreatment with the MMP inhibitors doxycycline or
ONO-4817 did not cause any change in Emax (Table 1), nor in the
concentration-response curves to phenylephrine and angiotensin II
in aortic rings from sham-operated animals (Fig. 1A and C). How-
ever, the single oral treatment with either doxycycline or ONO-4817
prevented CLP-induced hyporeactivity to KCl, phenylephrine and
angiotensin II (Table 1; Fig. 1B and D) (Po0.05 when compared
with the CLP-vehicle group). Notably, the comparison of the mean
differences between our two independent variables (sepsis and
MMP inhibitors) by means of two-way ANOVA revealed a consistent
interaction between these factors, which were of borderline of
statistical signiﬁcance for angiotensin II (P¼0.0569), and statistically
signiﬁcant for phenylephrine (P¼0.0385), conﬁrming that the
ability of MMP inhibitors to increase the reactivity for these two
vasoactive agents was dependent on the septic state.
High amounts of NOx
−, low leukocytes, lymphocytes and pla-
telets, as well as increased granulocytes, hemoglobin and hema-
tocrit were found in the blood of rats subjected to CLP, compared
with control (Po0.05). Despite the protective effect of doxycycline
and ONO-4817 against the vascular hyporeactivity to vasocon-
strictors, inhibition of MMP did not inﬂuence the augmented
blood levels of NOx
− (Fig. 2) nor the hematological impairment
found in the CLP group (Table 2).
3.2. Effects of CLP-induced sepsis on the activity and levels of MMPs
and tissue inhibitors of metalloproteinases (TIMPs) in aorta
homogenates
Using gelatin zymography we found augmented activity of
MMP-2 in aorta from the CLP group, compared with the untreated,
sham-operated animals (Po0.05). Doxycycline or ONO-4817
treatment did not alter the activity of MMP-2 in sham-operated
animals, but prevented its increase (Po0.05) in aortas from ani-
mals subjected to CLP (Fig. 3). As found for vascular reactivity, the
Fig. 1. Matrix metalloproteinase inhibitors prevent vascular refractoriness to vasoconstrictors 6 h after CLP-induced sepsis. The contractile effects induced by phenylephrine
and angiotensin II were measured in aortic rings from naïve and sham-operated rats (A and C), and animals subjected to the CLP model of sepsis (B and D), with or without
the previous oral administration of ONO-4817 (100 mg/kg) or doxycycline (15 mg/kg), given two hours before CLP or sham surgery. The results show the mean7S.E.M of 4–6
animals per group. *Po0.05 versus the respective control (sham-operated) group in panel A or C; #Po0.05 when either CLP-ONO-4817 or CPL-Doxycycline groups were
compared with the CLP-vehicle group.
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Fig. 2. Lack of effects of MMP inhibitors on serum nitrate and nitrite concentrations
measured at 6 h after CLP-induced sepsis. The levels of nitrate and nitrite were
detected in serum samples from naïve, sham-operated, or CLP rats previously
treated with ONO-4817 (100 mg/kg, p.o.), doxycycline (15 mg/kg, p.o.), or vehicle
(0.5% carboxymethylcellulose, 0.1 ml/100 g), given two hours before CLP or sham
surgery. The results show the mean7S.E.M of samples from 4–6 animals per
group. *Po0.05 versus sham-operated group.
Table 2
Lack of effects of doxycycline in the hematological changes induced by sepsis in the
CLP model.
Control CLP
– Vehicle Doxycycline
Leukocytes (103/ml) 11.1371.04 7.1270.67a 8.0570.9a
Hemoglobine (103/ml) 11.9470.33 16.1170.43a 13.8570.76a
Hematocrit (%) 44.9471.37 58.7370.84a 52.9872.89a
Platelets (103/ml) 850.60728.26 715.40751.84a 561.807125.70a
Lymphocytes (103/ml) 8.3270.82 3.2870.32a 3.8670.56a
Monocytes (103/ml) 1.0770.07 0.9270.06 1.1370.26
Granulocytes (103/ml) 1.7270.24 2.9170.33a 3.2070.34a
The values show the mean7standard error mean of samples collected from 6 dif-
ferent animals per group. CLP rats were previously treated with doxycycline (15
mg/kg, p.o.), or vehicle (0.5%carboxymethylcellulose, 0.1 ml/100 g), two hours be-
fore the CLP surgery.
a Po0.05 versus control group.
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niﬁcant for MMP-2 activity (P¼0.0086).
Western blot analysis revealed that the levels of MMP-2 protein
remain unchanged in aortas from the CLP group, and was not af-
fected by doxycycline or ONO-4817 in any experimental group
(Fig. 4A). In addition, we also detected increased levels of TIMP-1
in homogenates from CLP animals, compared with sham-operatedanimals (Po0.05). The treatment with ONO-4817 or doxycycline
did not change the protein levels of TIMP-1 detected in aortas from
sham-operated and CLP groups (Fig. 4B).
3.3. MMP inhibitors restore calponin-1 but not smoothelin-B levels
in the aorta of septic rats
Despite the absence of changes in the expression of smooth-
elin-B (Fig. 5A), the level of calponin-1 was reduced by 50% in
Fig. 3. MMP inhibitors prevent the enhanced activity of MMP-2 in aorta of rats at
6 h after CLP-induced sepsis. Gelatinolytic activity of MMP-2 in aorta homogenates
from naïve (NV), sham-operated, or CLP rats treated with ONO-4817 (ONO; 100 mg/
kg, p.o.), doxycycline (Dx; 15 mg/kg, p.o.), or vehicle (Veh; 0.5% carbox-
ymethylcellulose, 0.1 ml/100 g), two hours before CLP or sham surgery. The bands
were quantiﬁed as a ratio of the internal standard control (HT-1080), as indicated in
the representative experiment. The results show the mean7S.E.M of 3–5 experi-
ments with samples from different animals per group. *Po0.05 versus control
(sham-operated) group, and #Po0.05 when compared with the CLP-vehicle group.
Fig. 4. Western blot analyses for MMP-2 and TIMP-1 in aortas at 6 h after CLP-
induced sepsis. The 72 kDa MMP-2 (A) and 28 kDa TIMP-1 (B) were measured in
aorta homogenates from naïve, sham-operated, or CLP rats treated with ONO-4817
(100 mg/kg, p.o.), doxycycline (15 mg/kg, p.o.), or vehicle (0.5% carbox-
ymethylcellulose, 0.1 ml/100 g), at two hours before the CLP or sham surgery. The
results show the mean7S.E.M of 3–4 experiments with samples from different
animals per group. *Po0.05 versus control (sham-operated) group.
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Fig. 5. Prevention of loss of calponin-1, but not smoothelin-B, by MMP inhibitors in
aortas at 6 h after CLP-induced sepsis. The 100 kDa smoothelin-B (A) and the
34 kDa calponin-1 (B) were detected in aorta homogenates from naïve, sham-op-
erated, or CLP rats treated with ONO-4817 (100 mg/kg, p.o.), doxycycline (15 mg/kg,
p.o.), or vehicle (0.5% carboxymethylcellulose, 0.1 ml/100 g), two hours before CLP
or sham surgery. The results show the mean7S.E.M of 3–4 experiments with
samples from different animals per group. *Po0.05 versus control (sham-operated)
group, and #Po0.05 when compared with the CLP-vehicle group.
P. de Souza et al. / European Journal of Pharmacology 765 (2015) 164–170168aortas from rats subjected to CLP, compared with the sham-oper-
ated group (Fig. 5B). Importantly, the treatment with doxycycline
or ONO-4817 did not change the detected levels of calponin-1 in
the sham-operated groups, but completely abrogated the CLP-in-
duced reduction in this protein (Fig. 5B; P¼0.0707 for interaction
factor between sepsis and MMP inhibitors).4. Discussion
The major novelty of this study is that the oral administration
of MMP inhibitors, either doxycycline or ONO-4817, was able to
prevent sepsis-associated hyporeactivity to vasoconstrictors in
vessels from animals subjected to the polymicrobial CLP model of
sepsis.
Although MMPs have been previously associated with vascular
dysfunction in endotoxemic rats, the data presented herein re-
inforces the importance of MMPs or its associated targets in the
pathogenesis of vascular refractoriness to pressor agents in septic
shock, mainly because the CLP model induces a more aggressive
inﬂammatory scenario and resembles the complexity of human
sepsis, while the LPS-model is often subject to criticism, since it
does not reproduce the intensity and progression of infection-in-
duced septic shock in humans (for review see Dejager et al., 2011).
Doxycycline, the only MMP inhibitor approved for use in hu-
mans (Caton and Ryan, 2011), is a member of the tetracycline
antibiotics and has been described as anti-inﬂammatory in ex-
perimental models (Castro et al., 2011; Yrjanheikki et al., 1998).
Although we have not conducted experiments to evaluate its po-
tential antibacterial and anti-inﬂammatory effects, administration
P. de Souza et al. / European Journal of Pharmacology 765 (2015) 164–170 169of doxycycline did not improve any hematological parameter
commonly associated with sepsis in the CLP group, such as leu-
kopenia and thrombocytopenia, among others (Table 2), suggest-
ing that the low dose of doxycycline adopted in our study, given as
a single administration, did not present signiﬁcant antimicrobial
effects. ONO-4817 – also classiﬁed as a broad-spectrum MMP in-
hibitor, but without effects on the activity of MMP-1 and MMP-7 –
acts similarly to doxycycline and has also been known for its anti-
inﬂammatory properties (Golub et al., 1998; Naito et al., 2004;
Yamada et al., 2000). Importantly, neither doxycycline nor ONO-
4817 had any inﬂuence on the increased serum levels of NOx
− de-
tected in CLP rats. Accumulation of NOx
− in experimental sepsis
occurs due the high levels of nitric oxide released mainly by the
inducible isoform of the nitric oxide synthase, which in turn has its
expression stimulated by inﬂammatory cytokines produced in
response to infection (for review see Dinarello, 1997). Thus, the
unaltered serum NOx
− levels in septic rats treated with doxycycline
or ONO-4817 suggest that these drugs did not inﬂuence the in-
ﬂammatory proﬁle associated with the CLP model of sepsis, but
instead improved the vascular reactivity to vasoconstrictors by
their direct MMP inhibitory activity in vessels.
Previous evidence involving MMPs in the hyporeactivity to
vasoconstrictors in sepsis were restrict to the reduced vascular
responses to the α1-adrenergic agonist phenylephrine in the LPS
model. Importantly, the results obtained in this study not only
support these ﬁndings, but also disclosed the involvement of MMP
activity in reduced vasoconstriction to angiotensin II in aorta from
rats subjected to CLP. Low expression levels of both angiotensin II
and angiotensin converting enzyme have been suggested as an
indicative of poor prognosis in septic patients (Zhang et al., 2014).
In addition, a reduced expression of vascular angiotensin II AT1
receptor subtype has been suggested as a crucial event in ex-
perimental sepsis-induced hypotension (Bucher et al., 2001; Me-
derle et al., 2013). Taking into account the physiological vascular
effects and the severe hyporeactivity to angiotensin II found in
aortic rings from CLP rats, as well as the protection promoted by
either doxycycline or ONO-4817 (Fig. 1D), another important
ﬁnding of our study is that MMP activity contributes to vascular
hyporeactivity to diverse contractile agonizts potentially involved
in sepsis-induced vascular failure and severe hypotension. Notably,
vessels from sham-operated animals treated with MMP inhibitors
did not present any change in their reactivity to vasoconstrictors
when compared with control preparations (Fig. 1A and C), dis-
closing that the ability of both doxycycline and ONO-4817 to in-
crease the vascular reactivity to phenylephrine or angiotensin II
was restrict to aortic rings from septic animals, as evidenced by
the signiﬁcant interaction factor between sepsis and MMP-in-
hibitors found in our statistical analysis.
A number of metalloproteinases, including MMP-1, MMP-2,
MMP-3, MMP-7, MMP-9, MMP-12, MMP-13, and MMP-15, have
been involved in different vascular functions in both healthy and
disease states (for review see Chen et al., 2013; Galis and Khatri,
2002). Nevertheless, most of the vascular MMPs are described as
interstitial collagenases (i.e. MMP-1 and MMP-13), or are found
mainly in macrophages or other blood cells after their migration to
vessels (i.e. MMP-3, MMP-12 and MMP-13). This study was de-
signed to explore the inﬂuence of intracellular MMPs (i.e. MMP-2)
on the vascular responses to vasoconstrictors in the CLP model of
sepsis, but taking into account the poor selectivity of the MMP
inhibitors currently available, one important limitation of our
study is that we were unable to discard the individual participa-
tion of each MMP in the contractile function in our experiments.
Zymography and Western blot assays were carried out to better
explore and conﬁrm the correlation between the improved vas-
cular reactivity to vasoconstrictors and the inhibition of MMP-2 by
doxycycline and ONO-4817 in aortas from rats subjected to CLP. Aspreviously demonstrated for the LPS model (Lalu et al., 2006), we
found an augmented activity of the 72 kDa MMP-2 in vessels from
untreated CLP rats, which was prevented by doxycycline or ONO-
4817, and was not dependent on increased expression of MMP-2
protein, as detected by Western blot. MMPs can interact with
several structural and functional proteins involved in a number of
cellular functions. Their protective or deleterious participation in
cardiovascular diseases, including myocardial infarction, heart
failure, atherosclerosis, hypertension, stroke, and others, have
been extensively studied (for review see Ali et al., 2011; Castro
et al., 2011; Papazaﬁropoulou and Tentolouris, 2009). Never-
theless, neither the mechanisms involved in their activation nor
the cellular targets of MMPs are completely understood. Tissue
inhibitors of metalloproteinases (TIMPs) are recognized as the
main responsible for regulation of MMP activity in tissues, and the
reduction of these endogenous protease inhibitors could explain
the increased activity of MMP-2 found in our experiments. No-
tably, this hypothesis can be discarded based in the unaltered le-
vels of TIMP-4 (data not shown) and the increased levels of TIMP-1
(Fig. 4B) detected in aorta homogenates from CLP rats, which did
not present a different proﬁle in samples taken from animals
treated with MMP inhibitors. Although this study did not provide
additional insights regarding the mechanisms involved in MMP
activation, it is well known that sepsis is characterized by in-
creased biosynthesis of reactive oxygen- and nitrogen-species,
such as nitric oxide, superoxide and peroxynitrite (Rees et al.,
1990; Seija et al., 2012). Interestingly, it has been demonstrated
that peroxynitrite can activate 72 kDa MMP-2 (Viappiani et al.,
2009). Thus, considering the increased gelatinolytic activity found
for 72 kDa MMP-2 and the lack of detectable 64 kDa MMP-2 in our
experiments, it is reasonable to speculate that oxidative stress may
play an important role in the stimulation of vascular MMP-2 in
polymicrobial sepsis. However, the involvement of reactive oxygen
and nitrogen species and other mechanisms associated with the
vascular activation of MMPs in sepsis deserves further
investigation.
In spite of the description of a large number of predicted sub-
strates for MMP-2 in the vasculature (Chow et al., 2007), at least to
our knowledge only two regulatory proteins of vascular contrac-
tion, calponin-1 and smoothelin-B (Rensen et al., 2008; Takahashi
et al., 1988), had their role and interaction with MMPs in sepsis
previously investigated. Importantly, calponin-1, but not smooth-
elin-B, was characterized as a target of MMP-2 proteolysis in the
LPS model (Castro et al., 2012; de Souza et al., 2014). The lack of
changes in the levels of smoothelin-B and the signiﬁcant reduction
in the levels of calponin-1 found in aortas from CLP rats, a ﬁnding
fully prevented by both doxycycline and ONO-4817, conﬁrmed the
relationship between the enhanced activity of MMP-2 and calpo-
nin-1 also in the CLP model of sepsis.5. Conclusions
In summary, this study demonstrates, for the ﬁrst time in the
CLP model of sepsis, that polymicrobial sepsis is associated with
increased activity of MMP-2, augmented levels TIMP-1, and re-
duced amounts of calponin-1 in the aorta of rats. Importantly, all
these changes were prevented by doxycycline or ONO-4817, which
also protected against sepsis-induced vascular hyporeactivity to
both phenylephrine and angiotensin II, conﬁrming the role of
MMPs in the genesis of the vascular failure associated with septic
shock. These ﬁndings reinforce the importance of additional stu-
dies to evaluate the participation of MMPs in the functionality of
other vascular beds, including resistance vessels, as well as their
inﬂuence on vascular tone and tissue perfusion in later periods of
sepsis. The improved knowledge regarding the beneﬁcial or
P. de Souza et al. / European Journal of Pharmacology 765 (2015) 164–170170detrimental effects of MMP activity in the vasculature during
sepsis may provide better strategies in the future management of
vascular failure in patients with septic shock.Conﬂicts of interest
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